Tirzepatide
Mounjaro · Zepbound
A dual GIP and GLP-1 receptor agonist with a fatty-diacid modification for albumin binding, studied for glycemic control in type 2 diabetes and for weight management. Its half-life supports once-weekly administration.
Half-life
~5 days (~120 h), subcutaneous. Half-life is an educational pharmacology figure, drawn from public sources, and is not a schedule or dosing instruction.
Storage & handling
Supplied lyophilized; store cool, reconstitute before use, then refrigerate and protect from light.
References
- FDA approvals: Mounjaro (2022), Zepbound (2023)
- Schneck et al., CPT Pharmacometrics Syst Pharmacol 2024
Related in GLP-1 / Metabolic
Educational reference only, compiled from public sources. Not medical advice, diagnosis, treatment, or a dosing recommendation, and not a recommendation to use any compound. Many compounds listed are research materials not approved for human use. Consult a qualified professional.